CA2597701C - Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype - Google Patents

Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype Download PDF

Info

Publication number
CA2597701C
CA2597701C CA2597701A CA2597701A CA2597701C CA 2597701 C CA2597701 C CA 2597701C CA 2597701 A CA2597701 A CA 2597701A CA 2597701 A CA2597701 A CA 2597701A CA 2597701 C CA2597701 C CA 2597701C
Authority
CA
Canada
Prior art keywords
monoclonal antibody
human monoclonal
antibody
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2597701A
Other languages
English (en)
French (fr)
Other versions
CA2597701A1 (en
Inventor
Alois B. Lang
Michael P. Horn
Martin A. Imboden
Adrian Zuercher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenta Biotech AG
Original Assignee
Kenta Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech AG filed Critical Kenta Biotech AG
Publication of CA2597701A1 publication Critical patent/CA2597701A1/en
Application granted granted Critical
Publication of CA2597701C publication Critical patent/CA2597701C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2597701A 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype Expired - Fee Related CA2597701C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05003095A EP1690875A1 (en) 2005-02-14 2005-02-14 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
EP05003095.6 2005-02-14
PCT/EP2006/001289 WO2006084758A1 (en) 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype

Publications (2)

Publication Number Publication Date
CA2597701A1 CA2597701A1 (en) 2006-08-17
CA2597701C true CA2597701C (en) 2012-01-10

Family

ID=34933741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2597701A Expired - Fee Related CA2597701C (en) 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype

Country Status (11)

Country Link
US (1) US8197816B2 (OSRAM)
EP (2) EP1690875A1 (OSRAM)
JP (1) JP4944799B2 (OSRAM)
KR (2) KR20130018991A (OSRAM)
CN (1) CN101120018B (OSRAM)
AT (1) ATE480563T1 (OSRAM)
CA (1) CA2597701C (OSRAM)
DE (1) DE602006016736D1 (OSRAM)
ES (1) ES2348263T3 (OSRAM)
IL (1) IL184774A (OSRAM)
WO (1) WO2006084758A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208535A1 (en) * 2004-06-28 2009-08-20 Proteome Systems Intellectual Property Pty Ltd Novel Methods of Diagnosis of Treatment of P. Aeruginosa Infection and Reagents Therefor
KR20120016086A (ko) * 2009-04-09 2012-02-22 켄타 바이오테크 아게 슈도모나스 애루지노사 혈청형 ｉａｔｓ ０１의 지질다당류(ｌｐｓ) 특이적 인간 단일클론 항체
US20130022603A1 (en) * 2010-02-18 2013-01-24 Symphogen A/S Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits
SG11201602490UA (en) * 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Anti-lps o11 antibody
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
ES2994374T3 (en) 2017-01-18 2025-01-23 Visterra Inc Antibody molecule-drug conjugates and uses thereof
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
DE60130538T2 (de) 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CA2422204A1 (en) * 2000-09-07 2002-03-14 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice

Also Published As

Publication number Publication date
EP1848741A1 (en) 2007-10-31
US20090068191A1 (en) 2009-03-12
KR20130018991A (ko) 2013-02-25
ES2348263T3 (es) 2010-12-02
JP2008530988A (ja) 2008-08-14
IL184774A0 (en) 2007-12-03
US8197816B2 (en) 2012-06-12
CN101120018A (zh) 2008-02-06
ATE480563T1 (de) 2010-09-15
CN101120018B (zh) 2012-07-25
CA2597701A1 (en) 2006-08-17
JP4944799B2 (ja) 2012-06-06
KR20070107756A (ko) 2007-11-07
IL184774A (en) 2012-01-31
DE602006016736D1 (de) 2010-10-21
WO2006084758A1 (en) 2006-08-17
EP1848741B1 (en) 2010-09-08
EP1690875A1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
US6610293B1 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CA2769394C (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
IL184774A (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
US6962813B2 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
CA2525657C (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats o6 of pseudomonas aeruginosa
JP2009524428A (ja) スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質
US20120114657A1 (en) Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
US20060121045A1 (en) Antibody fragments for protection from pathogen infection and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210215